文献速递心力衰竭与心肌病心律失常

儿童与青少年心肌病:ESC注册研究揭示病因异质性与家族高发

Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry.
PubMed 文献 · Eur Heart J · 2024-01-01

该研究基于ESC EURObservational Research Programme心肌病与心肌炎长期注册,前瞻性纳入14国23家转诊中心633例≤18岁心肌病患者,中位诊断年龄4.0岁。HCM占61.3%、DCM占32.5%,47.3%有家族史,中位随访12.5个月死亡3.3%,RCM心衰事件最高(36.0%)。

要点

  • 儿童心肌病以HCM和DCM为主,RCM虽少但死亡与心衰事件比例最高。
  • 近半数患者有家族史,基因检测致病/可能致病变异检出率60.4%。
  • 10岁以下患者罕见疾病表型模拟更常见(30.9% vs 19.6%)。

核心结论

  • 儿童心肌病病因异质性强且家族性疾病比例高,结局因亚型而异,需疾病特异性评估与治疗。

研究设计与样本

  • 前瞻性注册研究,纳入2014年6月至2016年12月ESC EURObservational Research Programme心肌病与心肌炎长期注册中1-<18岁患者。
  • 共633例≤18岁患者,来自14国23家转诊中心,中位诊断年龄4.0岁(IQR 0-10),男性58.8%。

主要发现

  • HCM 388例(61.3%)、DCM 206例(32.5%)、RCM 28例(4.4%)、ARVC 11例(1.7%)。
  • 621例(98.1%)接受心脏药物治疗,80例(12.6%)植入ICD;253/535例(47.3%)有家族性疾病。
  • 414例(67.8%)行基因检测,250例(60.4%)报告致病或可能致病变异;177例(28.0%)有罕见疾病表型模拟。
  • 中位随访12.5个月(IQR 11.3-15.3),18例(3.3%)死亡:HCM 9例(2.6%)、DCM 5例(3.0%)、RCM 4例(16.0%);RCM心衰事件最频繁(36.0%)。

关键数值与推荐

  • 10岁以下患者罕见疾病表型模拟比例高于10岁及以上(30.9% vs 19.6%,P = .003)。

临床怎么用

  • 对儿童心肌病患者应常规评估家族史并考虑基因检测,以识别家族性疾病。
  • 按心肌病亚型进行风险分层,RCM患者需重点监测心力衰竭事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Childhood-onset cardiomyopathies are rare and poorly characterized. This study examined the baseline characteristics and 1-year follow-up of children with cardiomyopathy in the first European Cardiomyopathy Registry. METHODS: Prospective data were collected on individuals aged 1-<18 years enrolled in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis long-term registry (June 2014-December 2016). RESULTS: A total of 633 individuals aged ≤18 years with hypertrophic [HCM; n = 388 (61.3%)], dilated [DCM; n = 206 (32.5%)], restrictive [RCM; n = 28 (4.4%)], and arrhythmogenic right ventricular cardiomyopathy [ARVC; n = 11 (1.7%)] were enrolled by 23 referral centres in 14 countries. Median age at diagnosis was 4.0 [interquartile range (IQR) 0-10] years, and there was a male predominance [n = 372 (58.8%)] across all subtypes, with the exception of DCM diagnosed <10 years of age; 621 (98.1%) patients were receiving cardiac medication and 80 (12.6%) had an implantable cardioverter-defibrillator. A total of 253 patients (253/535, 47.3%) had familial disease. Genetic testing was performed in 414 (67.8%) patients with a pathogenic or likely pathogenic variant reported in 250 (60.4%). Rare disease phenocopies were reported in 177 patients (28.0%) and were most frequent in patients under 10 years [142 (30.9%) vs. 35 (19.6%); P = .003]. Over a median follow-up of 12.5 months (IQR 11.3-15.3 months), 18 patients (3.3%) died [HCM n = 9 (2.6%), DCM n = 5 (3.0%), RCM n = 4 (16.0%)]. Heart failure events were most frequent in RCM patients (36.0%). CONCLUSIONS: The findings confirm the heterogeneous aetiology of childhood cardiomyopathies and show a high frequency of familial disease. Outcomes differed by cardiomyopathy subtype, highlighting a need for disease-specific evaluation and treatment.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Kaski JP, Norrish G, Gimeno Blanes JR, et al. Cardiomyopathies in children and adolescents: aetiology, management, and outcomes in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis Registry. Eur Heart J. 2024. PMID: 38427064. doi:10.1093/eurheartj/ehae109

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。